Every day 1000 children die from a disease that no one talks about
Sickle cell disease is the world's most common genetic disorder, affecting over 12 million people, the disease kills half of children with the severe form before age five, predominantly impacting black populations.
Despite its high mortality, sickle cell remains largely underfunded and overlooked globally, with limited access to life-saving treatments.
This silent epidemic claims more children lives than...
Donate Now
Cathy Guetta Named Ambassador for Sickle Cell Disease
The 2nd Edition — Expanding Hope
Cathy Guetta, the iconic Queen of the Night and successful entrepreneur, is now channeling her boundless energy into a cause that urgently needs more visibility and funding: sickle cell disease.
Recently named Ambassador for Sickle Cell Disease by the International Sickle Cell Fund (ISCF), Cathy is bringing her trademark passion and drive to this global fight. Born in Dakar and raised in France, she’s not just lighting up her powerful network—she’s igniting hope.
Cathy is launching a series of high-impact fundraising events in support of both ISCFand the NGO Drep.Africa, with a bold mission: to help save thousands of children suffering from severe forms of this disease.
1st Edition Impact
€250,000
Raised during the gala
95%
Funds allocated to Drep.Afrique
1,000
Children in Senegal receiving 3 years of free treatment
300
African doctors trained via medical conference
Official launch of DREPAF
First sickle cell treatment produced in Africa
2026 Goal
Raise €300,000 to expand DREPAF access to Niger, Cameroon, Côte d'Ivoire, DRC, and Guinea.
An Unforgettable Night of Hope and Elegance
Thursday, July 16th, 2026 at Nikki Beach Saint-Tropez
Step into a world of chic sophistication and radiant glamour, where breathtaking decor meets the energy of an extraordinary cause.
With Cathy’s unique charisma and creative spirit, this Gala will transcend expectations to become a truly magical and unforgettable experience.
Good vibes, Emotions, and Great People
Exclusive auction – One-of-a-kind experiences & items
Your participation can save a child’s life.
DONATION PACKAGES:
- Individual seat – €500
- VIP Table (up to 8 guests) – €5,000
Sickle cell is #1 genetic disease in the World
Sickle cell disease is a genetic disorder affecting hemoglobin, the substance in red blood cells that carries oxygen. In affected individuals, red blood cells are fragile, destroyed quickly, and deformed into a sickle shape, obstructing blood flow and causing oxygen deprivation to organs.
This results in anemia, pain crises, and a higher risk of infections. Vaso-occlusive crises, marked by severe and unpredictable pain, can affect bones and organs.
In Africa, high infant mortality rates are due to limited access to treatment, exacerbating the disease's devastating impact. Despite its scale and devastating consequences, this disease remains largely overlooked.
- 80% of patients are in Africa.
- 50% of affected children die before the age of 5.
- < 20% of patients have access to hydroxyurea treatment
Early hope
Starting treatment at 9 months old can transform a child's life. We believe the fight against sickle cell disease must begin in infancy.
Every year, 300,000 to 400,000 babies are born with sickle cell disease worldwide. Eighty percent are born in Africa.
Most organizations focus on children — but the fight must start earlier. With proper diagnosis and access to treatments like DREPAF®, babies as young as 9 months can begin receiving life-saving care.
Cathy Guetta is personally committed to shining a light on infants and toddlers— children aged 1, 2, and 3 years old. Early intervention doesn't just extend life; it transforms futures.
Annual births
400K
babies born with sickle cell disease each year worldwide
Earliest treatment age
9 mo.
when babies can begin receiving life-saving care
We created ISC Fund to give access to the sickle cell treatment in Africa
The first treatment for Sickle Cell disease produced in Africa at cost
The International Sickle Cell Fund financially supports the NGO Drep Afrique, particularly the DREPAF® project.
The association has signed a unique humanitarian agreement with the laboratory Teranga Pharma to produce and distribute the only treatment that significantly reduces infant mortality among patients with Sickle Cell Disease using the hydroxyurea molecule.
The only hydroxyurea treatment offered at cost, priced between 25€ and 6$0 for a child weighing approximately 22 to 66 pounds (treatment cost may vary based on the dosage prescribed by the prescribing physician
The program will soon be available in four other African countries.
The first treatment for Sickle Cells disease produced in Africa at cost
The International Sickle Cell Fund financially supports the NGO Drep Afrique, particularly the DREPAF® project.
The association has signed a unique humanitarian agreement with the laboratory Teranga Pharma to produce and distribute the only treatment that significantly reduces infant mortality among patients with Sickle Cell Disease using the hydroxyurea molecule.
The only hydroxyurea treatment offered at cost, priced between 25€ and 60€ for a child weighing approximately 22 to 66 pounds (treatment cost may vary based on the dosage prescribed by the prescribing physician
The program will soon be available in four other African countries.
Distinguished Partners
In 2025, these prestigious brands joined Cathy Guetta to raise €250,000 for children with sickle cell disease.
Presented by 
You can save a life for 60€ per year
The generic hydroxyurea formulation DREPAF® is sold at cost price in Senegal, making it 3 to 10 times cheaper than the few treatments available (with limited access) in Africa
However, even at this reduced price, the poorest families with multiple children affected by the disease cannot afford the treatment.
This is why the International Sickle Cell Fund is reaching out to your generosity to help save thousands of children suffering from the severe form of the disease.
Together, we can change their lives!
Donate NowYou can save a life for 60€ per year
The generic hydroxyurea formulation DREPAF® is sold at cost price in Senegal, making it 3 to 10 times cheaper than the few treatments available (with limited access) in Africa
However, even at this reduced price, the poorest families with multiple children affected by the disease cannot afford the treatment.
This is why the International Sickle Cell Fund is reaching out to your generosity to help save thousands of children suffering from the severe form of the disease.
Together, we can change their lives!
Donate Now
We invite you to visit Drep Africa for detailed information about the NGO and its missions supported by the ISC Fund.
For any inquiries, please feel free to contact Emmanuel Jayr, Co-founder and Treasurer of the ISC Fund, at manu@iscfund.com.
© 2026 ISC Fund. All rights reserved